NMRA-215

A biotech funded by Shanghai Fosun Pharmaceutical is licensing a preclinical asset developed by Insilico Medicine in the NLRP3 space, which has garnered industry interest in recent months. Hygtia Therapeutics will get half the global rights for Insilico’s oral candidate, called ISM8969, in a deal that could total up to $66 million . Hong Kong-listed Insilico is set to receive $10 million within 30 days of the deal closing. It will be responsible for filing an IND and running a Phase 1 study in Parkinson’s disease. Hygtia will then take over further development and commercialization. NLRP3 is a protein that plays a key role in the innate immune system. Its abnormal activation is thought to drive neuroinflammation in diseases like Alzheimer’s and Parkinson’s. Several companies have recently made moves in the NLRP3-targeting space. This month, Eli Lilly signed a $1.2 billion deal to buy Ventyx Biosciences, which has a mid-stage candidate called VTX3232 in development for patients with obesity and cardiovascular risk factors. Ventyx is developing several NLRP3 inhibitors for autoimmune, cardiovascular and neurological diseases. In October last year, Neumora shared plans to advance its NLRP3 inhibitor, called NMRA-215, into a Phase 1 obesity trial this year. NodThera, Olatec and BioAge Labs are also working on the target in various therapeutic areas. But some attempts in the space have yielded mixed results. In October, Ventus Therapeutics terminated a Phase 2 trial of its NLRP3 inhibitor, known as VENT-02, in Parkinson’s disease without providing an explanation. Ventyx’s VTX3232 also failed to reduce weight in obese patients enrolled in Phase 2, although it did significantly reduce key biomarkers for cardiovascular risk. For Parkinson’s, Insilico believes ISM8969 differs from other drugs in the same class because it can penetrate the blood-brain barrier and was designed with the help of its Chemistry42 platform. Hygtia was incubated by Shenzhen Pengfu Fund, which is backed by Fosun Health Capital and Fosun Pharma. The biotech was founded in August last year with a focus on advancing treatments for autoimmune diseases and “related areas.”